Skip to main content
Stephanie Lheureux on Muck Rack

Stephanie Lheureux

As seen in: Nature, MDPI, Genome Medicine, JAMA Oncology, Medscape, Science Magazine, The Lancet, Dove Medical Press, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stephanie

Contact Stephanie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

|
By Lucy Roxana Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, Anna Jaeger, Linn Woelber, Hannah Woopen, Jean-Sébastien Frenel, Katharina Bischof, Allison L Brodsky, Jonathan A. Ledermann, Talayeh S. Ghezelayagh, Ingrid A. Boere, Sabrina Kaiser, Constanza Maximiano, Tamar Safra, Sabrina Chiara Cecere, Isabelle Ray-Coquard, Stephanie Lheureux, Ros Glasspool, Marta Gil-Martin, IK Kim, Suzana Mittelstadt, Miguel Aparicio, Isabel Aguilar Palacio, Rebecca S Kristeleit, Nelleke PB. Ottevanger, Maria Varela Verified, Hiroyuki Yoshida, Theresa Link, Lydia Gaba, Gloria Marquina, Nikki Burdett, Paul Johannet, Juliane Reichenbach, Antonio González-Martín, Christian Marth, Sabine Heublein, Lawrence Kasherman, Cristina Perez, Cristina Pérez Verified, María Masvidal, Nikolaus de Gregorio, Felix Hilpert, Jalid Sehouli, Clare Scott Verified, Katherine Tucker, Jack Dong, Cristina Fortuno, Amanda B. Spurdle, Michael Friedlander, Anna V Tinker, Andrew Clamp, Iain A. McNeish, Nicoletta Colombo, Sandro Pignata, Kristina Lindemann, Patricia Roxburgh, Jae-Weon Kim, Shannon N. Westin, Jonathan S. Berek, William P. Tew, Carol Aghajanian, Philipp Harter, Madeline Rhind, Aanum Aanum, Marta Mongillo, Ora Rosengarten, Ana Pertejo, Laura Tookman, Cristina Martin-Lorente, Helena de la Cueva, Tjoung-Won Park-Simon, Philip H. Klecker, Clemens Liebrich, Levan Dzotsenidze, Pau Guillén Sentís, Franziska Hemptenmacher, Susan Ellard
| JAMA Oncology Verified
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors Supplement 1. eTable 2. Electronic Database Questionnaire eTable 3. Second Primary Cancers eTable 4. Overview of Characteristics of BRCA1 and BRCA2 Pathogenic Variants Documented in Exceptional Responders eTable 5. Variant Characteristics for Exceptional Responders Compared to Those for PAOLA-1 Trial Participants eTable 6.
Open in Who Shared Issue with article?

From Carcinosarcoma to Circulating Tumor DNA: The Importance of Investigator-Initiated Research in Endometrial Cancer

|
By Ursula Matulonis, Stephanie Lheureux
| Medscape Verified
Episode Transcript This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I’m Dr Ursula Matulonis. Welcome to season 3 of the Medscape InDiscussion endometrial cancer podcast series.
Open in Who Shared Issue with article?

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

|
By Ana C. Veneziani, Stephanie Lheureux, Douglas G. Millar, Neesha Dhani, Ilaria Colombo, Ainhoa Madariaga, Pamela Piña, Joshua Lee, Lisa Wang, Xuan Li, Ben Wang, Amit M Oza, Swati Atale, Yin-Ling Chan, Janelle Ramsahai, Judy Quintos, Valerie Bowering, Pam Ohashi
| Nature Verified
Abstract This investigator-initiated, open-label phase 1/2 clinical trial evaluates maveropepimut-S, a survivin-targeting vaccine, combined with pembrolizumab and low-dose cyclophosphamide in patients with recurrent epithelial ovarian cancer (ClinicalTrials.gov identifier: NCT03029403). The primary endpoints are safety and clinical efficacy measured by overall response rate and disease control rate.
Open in Who Shared Issue with article?
See all 17 articles